Filing Overview
Issuer and period: The supplied Form 10-Q identifies the registrant as Aileron Therapeutics, Inc., not Rein Therapeutics, Inc. It covers the quarter and nine months ended September 30, 2017, and was filed November 9, 2017. The financial statements are unaudited.
Business Context and Reporting Period
Aileron was a clinical-stage biopharmaceutical company developing stapled-peptide therapeutics. Its lead candidate, ALRN-6924, targeted the p53 pathway for cancer treatment and was being evaluated in Phase 1 and Phase 2a clinical programs covering solid tumors, lymphomas, AML and MDS. The company had no approved products and no product revenue.
Financial Performance and Liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $3.825 million | $9.928 million |
| General and administrative expense | $2.601 million | $6.039 million |
| Total operating expenses | $6.426 million | $15.967 million |
| Net loss | $6.259 million | $15.739 million |
| Net loss attributable to common stockholders | $6.259 million | $15.780 million |
| Basic and diluted loss per share | $0.45 loss | $3.16 loss |
| Cash used in operating activities | Not separately provided | $14.693 million |
Balance sheet: At September 30, 2017, cash and cash equivalents were $13.428 million, investments were $43.437 million, and total cash, cash equivalents and investments were approximately $56.9 million. Total assets were $59.036 million, current liabilities were $5.023 million, and stockholders’ equity was $54.013 million. The filing does not disclose outstanding debt; reported liabilities primarily consisted of accounts payable and accrued expenses.
Cash flows: Investing activities used $43.429 million, primarily reflecting purchases of short-term investments. Financing activities provided $50.835 million, primarily from the IPO. Cash and cash equivalents declined by $7.287 million to $13.428 million during the nine-month period.
Margins: Operating and net margins are not meaningful because the company generated no revenue and remained in the clinical-development stage.
Material Changes Versus the Prior Comparable Period
- Third-quarter R&D expense increased $1.220 million, or approximately 47%, to $3.825 million, primarily from higher ALRN-6924 clinical-trial and manufacturing costs.
- Third-quarter G&A expense increased $0.974 million, or approximately 60%, to $2.601 million, driven by higher stock-based compensation and public-company professional costs.
- Nine-month R&D expense increased $2.744 million, or approximately 38%, while nine-month G&A expense decreased $0.498 million. The prior-year period included a $1.5 million write-off of deferred offering costs.
- Nine-month net loss increased $2.058 million to $15.739 million, and operating cash use increased from $10.781 million to $14.693 million.
- The July 2017 IPO generated $50.0 million of net proceeds. All outstanding redeemable convertible preferred stock converted into 10.510 million common shares, eliminating the preferred-stock balance and substantially increasing equity.
- Common shares outstanding increased to 14,718,787 at September 30, 2017 from 432,413 at December 31, 2016, reflecting the preferred-stock conversion, IPO and other equity activity.
Outlook, Risks and Unusual Items
- Management expected continuing losses and materially higher expenses as clinical development of ALRN-6924 and other programs progressed.
- Management stated that September 30 cash, cash equivalents and investments were expected to fund operating and capital requirements through at least the next twelve months; the MD&A provided a more specific estimate through the second quarter of 2019. These estimates depended on assumptions that could prove inaccurate.
- Additional financing was expected to be necessary. Potential sources included equity or debt offerings, collaborations, licensing transactions and other strategic arrangements. No committed external funding source was disclosed.
- Key contingencies included clinical-trial failure or delay, patient-enrollment challenges, adverse safety findings, regulatory rejection, manufacturing dependence, intellectual-property disputes and the possible need for a companion diagnostic for a wild-type p53 label.
- The company relied on third-party contract research and manufacturing organizations and had no manufacturing facilities or personnel of its own. It did not have redundant supply arrangements for ALRN-6924 active pharmaceutical ingredient.
- A Harvard license dispute concerning diligence milestones remained a stated risk. Harvard had previously proposed converting certain exclusive rights to non-exclusive rights; the company rejected the proposal, and no subsequent termination action had been reported.
- The office and laboratory lease was scheduled to expire in May 2018, with disclosed remaining minimum payments of $135,000 for the final three months of 2017 and $202,000 for 2018.
- No material legal proceedings, off-balance-sheet arrangements or material changes in internal control were reported. Management concluded disclosure controls were effective as of September 30, 2017.
Investor Verification Checklist
- Verify the issuer identity: the supplied filing is for Aileron Therapeutics, Inc., while the request names Rein Therapeutics, Inc.
- Reconcile the liquidity runway statements: the notes reference at least twelve months, while MD&A states funding through the second quarter of 2019.
- Confirm the company’s cash-burn rate, clinical-trial spending and timing of additional financing needs.
- Review clinical results, enrollment status and regulatory developments for ALRN-6924, including companion-diagnostic requirements.
- Assess the status of the Harvard/DFCI license rights and any future milestone, royalty or termination exposure.
- Evaluate dilution from the 2.055 million outstanding stock options, future equity financing and shares becoming eligible for resale after the IPO lock-up expiration.